Early detection of cancer in the general population: A blinded case-control study of p53 autoantibodies in colorectal cancer

British Journal of Cancer

Volumn 108, Issue 1, 2013, Pages 107-114

  Pedersen, J W ^a   Gentry Maharaj, A ^b   Fourkala, E O ^b   Dawnay, A ^c   Burnell, M ^b   Zaikin, A ^b   Pedersen, A E ^d   Jacobs, I ^b   Menon, U ^b   Wandall, H H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

autoantibodies; biomarkers; colon; microarray; p53; rectum

Indexed keywords

AUTOANTIBODY; PROTEIN P53 ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIBODY DETECTION; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CASE CONTROL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MICROARRAY ANALYSIS; ORAL CONTRACEPTION; OVARY CANCER; PARITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SEROLOGY; SINGLE BLIND PROCEDURE; SPONTANEOUS ABORTION;

AGED; AUTOANTIBODIES; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; POPULATION SURVEILLANCE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872595604     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.517     Document Type: Article

References (41)

1. Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, Wood WC, Maddison P, Healey G, Fairley GH, Barnes AC, Robertson JF (2011) Clinical validation of an autoantibody test for lung cancer. Ann Oncol 22: 383-389.
2. Burnell M, Gentry-Maharaj A, Ryan A, Apostolidou S, Habib M, Kalsi J, Skates S, Parmar M, Seif MW, Amso NN, Godfrey K, Oram D, Herod J, Williamson K, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Leeson S, Cruickshank D, Campbell S, Fallowfield L, Jacobs I, Menon U (2011) Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials. Trials 12: 61.
3. Casey G, Lopez ME, Ramos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B, Slamon DJ (1996) DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13: 1971-1981.
4. Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkin SS, Fishman D, Munkarah A, Morris R, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S, Tainsky MA (2006) Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 66: 1181-1190.
5. Fourkala EO, Gentry-Maharaj A, Burnell M, Ryan A, Manchanda R, Dawnay A, Jacobs I, Widschwendter M, Menon U (2012) Histological confirmation of breast cancer registration and self-reporting in England and Wales: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening. Br J Cancer 106: 1910-1916.
6. Hallak R, Mueller J, Lotter O, Gansauge S, Gansauge F, el-Deen Jumma M, Montenarh M, Safi F, Beger H (1998) p53 genetic alterations, protein expression and autoantibodies in human colorectal carcinoma: a comparative study. Int J Oncol 12: 785-791.
7. Houbiers JG, van der Burg SH, van de Watering LM, Tollenaar RA, Brand A, van de Velde CJ, Melief CJ (1995) Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 72: 637-641.
8. Jacobs I, Menon U (2011) The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples. Cancer Prev Res 4: 299-302.
9. Kressner U, Glimelius B, Bergstrom R, Pahlman L, Larsson A, Lindmark G (1998) Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer 77: 1848-1851.
10. Labrecque S, Naor N, Thomson D, Matlashewski G (1993) Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 53: 3468-3471.
11. Lechpammer M, Lukac J, Lechpammer S, Kovacevic D, Loda M, Kusic Z (2004) Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis 19: 114-120.
12. Li M, Chen WD, Papadopoulos N, Goodman SN, Bjerregaard NC, Laurberg S, Levin B, Juhl H, Arber N, Moinova H, Durkee K, Schmidt K, He Y, Diehl F, Velculescu VE, Zhou S, Diaz Jr LA, Kinzler KW, Markowitz SD, Vogelstein B (2009) Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 27: 858-863.
13. Li Y, Karjalainen A, Koskinen H, Hemminki K, Vainio H, Shnaidman M, Ying Z, Pukkala E, Brandt-Rauf PW (2005) p53 autoantibodies predict subsequent development of cancer. Int J Cancer 114: 157-160.
14. Liu W, Wang P, Li Z, Xu W, Dai L, Wang K, Zhang J (2009) Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer. Scand J Immunol 69: 57-63.
15. Lu D, Kuhn E, Bristow RE, Giuntoli 2nd RL, Kjaer SK, Shih IM, Roden RB (2011) Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol 122: 560-566.
16. Lu H, Ladd J, Feng Z, Wu M, Goodell V, Pitteri SJ, Li CI, Prentice RL, Hanash SM, Disis ML (2012) Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in pre-diagnostic breast cancer sera. Cancer Prev Res 5: 1036-1043.
17. Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Tredaniel J, Hirsch A, de Fromentel CC, Preudhomme C, Fenaux P, Fournier G, Mangin P, Laurent-Puig P, Pelletier G, Schlumberger M, Desgrandchamps F, Le Duc A, Peyrat JP, Janin N, Bressac B, Soussi T (1993) Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 53: 5872-5876.
18. Lubin R, Zalcman G, Bouchet L, Tredanel J, Legros Y, Cazals D, Hirsch A, Soussi T (1995) Serum p53 antibodies as early markers of lung cancer. Nat Med 1: 701-702.
19. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, Godfrey K, Oram D, Herod J, Williamson K, Seif MW, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso NN, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Singh N, Dawnay A, Skates SJ, Parmar M, Jacobs I (2009) Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10: 327-340.
20. Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, Lewis S, Lopez A, Godfrey K, Oram D, Herod J, Williamson K, Seif M, Scott I, Mould T, Woolas R, Murdoch J, Dobbs S, Amso N, Leeson S, Cruickshank D, McGuire A, Campbell S, Fallowfield L, Skates S, Parmar M, Jacobs I (2008) Recruitment to multicentre trials-lessons from UKCTOCS: descriptive study. BMJ 337: a2079.
21. Nielsen HJ, Jakobsen KV, Christensen IJ, Brunner N (2011) Screening for colorectal cancer: possible improvements by risk assessment evaluation? Scand J Gastroenterol 46: 1283-1294.
22. Pedersen JW, Blixt O, Bennett EP, Tarp MA, Dar I, Mandel U, Poulsen SS, Pedersen AE, Rasmussen S, Jess P, Clausen H, Wandall HH (2011) Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer 128: 1860-1871.
23. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD (2008) Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 100: 1432-1438.
24. Pitteri SJ, Hanash SM (2011) Confounding effects of hormone replacement therapy in protein biomarker studies. Cancer Epidemiol Biomarkers Prev 20: 134-139.
25. Qiu J, Choi G, Li L, Wang H, Pitteri SJ, Pereira-Faca SR, Krasnoselsky AL, Randolph TW, Omenn GS, Edelstein C, Barnett MJ, Thornquist MD, Goodman GE, Brenner DE, Feng Z, Hanash SM (2008) Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 26: 5060-5066.
26. Rohayem J, Conrad K, Zimmermann T, Frank KH (1999) Comparison of the diagnostic accuracy of three commercially available enzyme immunoassays for anti-p53 antibodies. Clin Chem 45: 2014-2016.
27. Saleh J, Kreissler-Haag D, Montenarh M (2004) p53 autoantibodies from patients with colorectal cancer recognize common epitopes in the N-or C-terminus of p53. Int J Oncol 25: 1149-1155.
28. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T (1992) The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52: 6380-6384.
29. Schlichtholz B, Tredaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T (1994) Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 69: 809-816.
30. Soussi T (2000) p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60: 1777-1788.
31. Sthoeger Z, Evron E, Goland S, Shani A, Wolkowicz R, Goldfinger N, Rotter V, Fogel M (1997) Anti-p53 autoantibodies in colon cancer patients. Ann N Y Acad Sci 815: 496-498.
32. Suppiah A, Alabi A, Madden L, Hartley JE, Monson JR, Greenman J (2008) Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up. Int J Colorectal Dis 23: 595-600.
33. Tang R, Ko MC, Wang JY, Changchien CR, Chen HH, Chen JS, Hsu KC, Chiang JM, Hsieh LL (2001) Humoral response to p53 in human colorectal tumors: a prospective study of 1, 209 patients. Int J Cancer 94: 859-863.
34. Tanzer M, Balluff B, Distler J, Hale K, Leodolter A, Rocken C, Molnar B, Schmid R, Lofton-Day C, Schuster T, Ebert MP (2010) Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One 5: e9061.
35. Trivers GE, Cawley HL, DeBenedetti VM, Hollstein M, Marion MJ, Bennett WP, Hoover ML, Prives CC, Tamburro CC, Harris CC (1995) Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst 87: 1400-1407.
36. Trivers GE, De Benedetti VM, Cawley HL, Caron G, Harrington AM, Bennett WP, Jett JR, Colby TV, Tazelaar H, Pairolero P, Miller RD, Harris CC (1996) Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 2: 1767-1775.
37. Vennegoor CJ, Nijman HW, Drijfhout JW, Vernie L, Verstraeten RA, von Mensdorff-Pouilly S, Hilgers J, Verheijen RH, Kast WM, Melief CJ, Kenemans P (1997) Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes. Cancer Lett 116: 93-101.
38. Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM (2005) Autoantibody signatures in prostate cancer. N Engl J Med 353: 1224-1235.
39. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP (1992) Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52: 4168-4174.
40. Zervoudakis A, Strickler HD, Park Y, Xue X, Hollenbeck A, Schatzkin A, Gunter MJ (2011) Reproductive history and risk of colorectal cancer in postmenopausal women. J Natl Cancer Inst 103: 826-834.
41. Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA (2006) Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol 1: 513-519.